Surveyed U.S. Gastroenterologists and MCO Pharmacy Directors Say Improvement in Overall Symptoms of IBS Remains a Significant Unmet Need; Asimadoline, Mudelta and LX-1033 Have Demonstrated the Potential to Partially Fulfill 